SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Drug-loaded erythrocytes: on the road toward marketing approval.

Bourgeaux, V; Lanao, JM; Bax, BE; Godfrin, Y (2016) Drug-loaded erythrocytes: on the road toward marketing approval. Drug Des Devel Ther, 10. pp. 665-676. ISSN 1177-8881 https://doi.org/10.2147/DDDT.S96470
SGUL Authors: Bax, Bridget Elizabeth

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (656kB) | Preview

Abstract

Erythrocyte drug encapsulation is one of the most promising therapeutic alternative approaches for the administration of toxic or rapidly cleared drugs. Drug-loaded erythrocytes can operate through one of the three main mechanisms of action: extension of circulation half-life (bioreactor), slow drug release, or specific organ targeting. Although the clinical development of erythrocyte carriers is confronted with regulatory and development process challenges, industrial development is expanding. The manufacture of this type of product can be either centralized or bedside based, and different procedures are employed for the encapsulation of therapeutic agents. The major challenges for successful industrialization include production scalability, process validation, and quality control of the released therapeutic agents. Advantages and drawbacks of the different manufacturing processes as well as success key points of clinical development are discussed. Several entrapment technologies based on osmotic methods have been industrialized. Companies have already achieved many of the critical clinical stages, thus providing the opportunity in the future to cover a wide range of diseases for which effective therapies are not currently available.

Item Type: Article
Additional Information: This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
Keywords: clinical use, drug carrier, encapsulation method, industrial development, red blood cell, 1115 Pharmacology And Pharmaceutical Sciences
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Academic Structure > Molecular and Clinical Sciences Research Institute (MCS) > Cell Sciences (INCCCS)
Journal or Publication Title: Drug Des Devel Ther
ISSN: 1177-8881
Language: ENG
Dates:
DateEvent
30 October 2015Accepted
11 February 2016Published
Publisher License: Creative Commons: Attribution-Noncommercial 3.0
PubMed ID: 26929599
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/107751
Publisher's version: https://doi.org/10.2147/DDDT.S96470

Actions (login required)

Edit Item Edit Item